Fecal dissemination of SARS-CoV-2 virus genome in COVID-19 patients in India
Fecal dissemination of SARS-CoV-2 virus genome in COVID-19 patients in India. Spencer EA, Heneghan C.
Published on July 16, 2020
Transmission Dynamics of COVID-19
||Senapati S, Kshatri JS, Prasad P et al. A pilot study to investigate the fecal dissemination of SARS-CoV-2 virus genome in COVID-19 patients in Odisha, India. medRxiv 2020.05.26.20113167; doi: https://doi.org/10.1101/2020.05.26.20113167
This pilot study in India found SARS-CoV-2 RNA in fecal samples from 12 symptomatic and asymptomatic COVID-19 patients.
SARS-CoV-2 RNA was identified in fecal samples from 12 COVID-19 patients, some of whom were asymptomatic Transmission of infectious virus was not confirmed by this study
The study established a protocol to collect and extract viral RNA for SARS-CoV-2 detection in fecal samples.
What did they do?
This was a pilot study to investigate fecal dissemination of the SARS-CoV-2 genome among Indian COVID-19 patients.
Patients admitted to a COVID-19 hospital were tested by nasopharyngeal swab and rectal swab, performed on the same day. These were tested for SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR).
This is a pilot study and not sufficiently powered to generate reliable findings – the study sets up the protocol for a large study to investigate possible transmission. It is unclear how the 12 patients for whom data are presented were selected.
|Clearly defined setting
||Demographic characteristics described
||Follow-up length was sufficient
||Transmission outcomes assessed
||Main biases are taken into consideration
What else should I consider?
It is unclear why patients who were asymptomatic had been admitted as it was a COVID-19 hospital, or if they mean that patients had become asymptomatic during their hospital stay but nevertheless gave nasopharyngeal and rectal samples.
Next research steps are to perform a large study to correlate the significance of the SARS-CoV-2 virus genome detection in fecal samples with disease severity and transmission.
About the authors
Carl is Professor of EBM & Director of CEBM at the University of Oxford. He is also a GP and tweets @carlheneghan. He has an active interest in discovering the truth behind health research findings
Dr Elizabeth Spencer; MMedSci, PhD. Epidemiologist, Nuffield Department for Primary Care Health Sciences, University of Oxford.
Tom Jefferson, epidemiologist.